menu

ReachMD

Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central

Join expert faculty to ensure you’re appropriately managing the care of your patients with ASCVD.

Live Broadcast
3.00 available credits
Information
April 04, 2022
06:30 PM - 09:30 PM CDT
On Line
ReachMD Healthcare Image
Details
Presenters
Related
Comments

  • Overview

    Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided. 

    Please see when the Live Broadcast will begin in your timezone:

    • 7:30 PM ET
    • 6:30 PM CT
    • 5:30 PM MT
    • 4:30 PM PT

  • Program Schedule*

    6:30 PM–6:35 PM

    Welcome, Introductions, Program Overview
    Christie Ballantyne, MD
    Program Chair

    6:35 PM–6:45 PM

    Burden of Heart Disease Today
    Christie Ballantyne, MD

    6:45 PM–7:05 PM

    Atherogenic Dyslipidemia and New Approaches to Risk Assessment for ASCVD
    Gregory Pokrywka, MD

    7:05 PM–7:30 PM

    REDUCE-IT Clinical Trials and Omega 3 Fatty Acids for ASCVD Risk Reductions
    Karol Watson, MD

    7:30 PM–7:45 PM

    Panel Discussion
    All faculty

    7:45 PM–8:00 PM

    Break

    8:00 PM–8:15 PM

    Recent Evidence from REDUCE-IT Sub-studies
    Karol Watson, MD

    8:15 PM–8:35 PM

    Differential Biological Effects of Omega-3 Fatty Acids
    Gregory Pokrywka, MD

    8:35 PM–8:55 PM

    Role of Pharmacist in Establishing Lipid Intervention
    Joseph Saseen, PharmD, BCPS, BCACP

    8:55 PM–9:10 PM

    Panel Discussion
    All Faculty

     9:10 PM–9:25 PM

    Clinical Approaches to Personalizing Medical Management of ASCVD Risk Factors
    All Faculty

    9:25 PM–9:30 pm   

    Closing Comments, Adjourn
    Karol Watson, MD

    *Subject to change

    Click Here to Download Slide Presentation

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Chair:
    Christie M. Ballantyne, MD
    Chief, Sections of Cardiology and Cardiovascular Research
    Professor and Vice Chair of Research
    J.S. Abercrombie Chair, Atherosclerosis & Lipoprotein Research
    Department of Medicine
    Director, Center for Cardiometabolic Disease Prevention
    Baylor College of Medicine
    Houston, TX
    Research: Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, lonis, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic.
    Consulting Fees: Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, lllumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo

    Faculty:
    Gregory S. Pokrywka, MD, FACP, FNLA, FASPC, NCMP
    Director: Baltimore Lipid Center
    Assistant Professor
    Johns Hopkins University School of Medicine
    Baltimore, MD

    Commercial Interest Speakers Bureau: Amarin, Amgen, Esperion 

    Joseph Saseen, PharmD
    Professor, Departments of Clinical Pharmacy and Family Medicine
    Vice Chair, Department of Clinical Pharmacy
    Skaggs School of Pharmacy and Pharmaceutical Sciences
    University of Colorado Anschutz Medical Campus
    Aurora, CO

    No relationship reported

    Karol Watson, MD, PhD
    Professor of Medicine/Cardiology
    Co-director, UCLA Program in Preventive Cardiology
    Director, UCLA Barbra Streisand Women's Heart Health Program
    David Geffen School of Medicine at UCLA
    Los Angeles, CA

    Consulting Fees: Amarin, Amgen, Boehringer-Ingelheim, Lilly, Esperion, Novo Nordisk

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose
    • Cindy Davidson has nothing to disclose.
    • Libby Lurwick has nothing to disclose
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, MS has nothing to disclose.
    • Kathy Wickman has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
    • Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
    • Identify barriers to the implementation of effective, long-term management of ASCVD

  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians and community pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Presenters

Related

  • ASCVD

    Adopting the New Therapeutic “Lineup” to Manage ASCVD - Slides

    Show more

Facebook Comments

Details
Presenters
Related
Comments
Recommended

  • Overview

    Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided. 

    Please see when the Live Broadcast will begin in your timezone:

    • 7:30 PM ET
    • 6:30 PM CT
    • 5:30 PM MT
    • 4:30 PM PT

  • Program Schedule*

    6:30 PM–6:35 PM

    Welcome, Introductions, Program Overview
    Christie Ballantyne, MD
    Program Chair

    6:35 PM–6:45 PM

    Burden of Heart Disease Today
    Christie Ballantyne, MD

    6:45 PM–7:05 PM

    Atherogenic Dyslipidemia and New Approaches to Risk Assessment for ASCVD
    Gregory Pokrywka, MD

    7:05 PM–7:30 PM

    REDUCE-IT Clinical Trials and Omega 3 Fatty Acids for ASCVD Risk Reductions
    Karol Watson, MD

    7:30 PM–7:45 PM

    Panel Discussion
    All faculty

    7:45 PM–8:00 PM

    Break

    8:00 PM–8:15 PM

    Recent Evidence from REDUCE-IT Sub-studies
    Karol Watson, MD

    8:15 PM–8:35 PM

    Differential Biological Effects of Omega-3 Fatty Acids
    Gregory Pokrywka, MD

    8:35 PM–8:55 PM

    Role of Pharmacist in Establishing Lipid Intervention
    Joseph Saseen, PharmD, BCPS, BCACP

    8:55 PM–9:10 PM

    Panel Discussion
    All Faculty

     9:10 PM–9:25 PM

    Clinical Approaches to Personalizing Medical Management of ASCVD Risk Factors
    All Faculty

    9:25 PM–9:30 pm   

    Closing Comments, Adjourn
    Karol Watson, MD

    *Subject to change

    Click Here to Download Slide Presentation

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Chair:
    Christie M. Ballantyne, MD
    Chief, Sections of Cardiology and Cardiovascular Research
    Professor and Vice Chair of Research
    J.S. Abercrombie Chair, Atherosclerosis & Lipoprotein Research
    Department of Medicine
    Director, Center for Cardiometabolic Disease Prevention
    Baylor College of Medicine
    Houston, TX
    Research: Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, lonis, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic.
    Consulting Fees: Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, lllumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo

    Faculty:
    Gregory S. Pokrywka, MD, FACP, FNLA, FASPC, NCMP
    Director: Baltimore Lipid Center
    Assistant Professor
    Johns Hopkins University School of Medicine
    Baltimore, MD

    Commercial Interest Speakers Bureau: Amarin, Amgen, Esperion 

    Joseph Saseen, PharmD
    Professor, Departments of Clinical Pharmacy and Family Medicine
    Vice Chair, Department of Clinical Pharmacy
    Skaggs School of Pharmacy and Pharmaceutical Sciences
    University of Colorado Anschutz Medical Campus
    Aurora, CO

    No relationship reported

    Karol Watson, MD, PhD
    Professor of Medicine/Cardiology
    Co-director, UCLA Program in Preventive Cardiology
    Director, UCLA Barbra Streisand Women's Heart Health Program
    David Geffen School of Medicine at UCLA
    Los Angeles, CA

    Consulting Fees: Amarin, Amgen, Boehringer-Ingelheim, Lilly, Esperion, Novo Nordisk

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose
    • Cindy Davidson has nothing to disclose.
    • Libby Lurwick has nothing to disclose
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, MS has nothing to disclose.
    • Kathy Wickman has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
    • Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
    • Identify barriers to the implementation of effective, long-term management of ASCVD

  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians and community pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Presenters

Related

  • ASCVD

    Adopting the New Therapeutic “Lineup” to Manage ASCVD - Slides

    Show more

Facebook Comments

Recommended

Schedule5 Dec 2022
PrevNext

Segment Chapters

Playlist:

Recommended